HOOKIPA Pharma Inc. announced that the European Medicines Agency (EMA) has granted PRIME designation for the investigational product HB-200 in combination with pembrolizumab for the treatment of patients with Human Papillomavirus 16-positive (HPV16+) recurrent/metastatic PD-L1 CPS = 20 oropharyngeal squamous cell carcinoma (OPSCC) in the first line setting. PRIME designation is intended to expedite development and review of drug candidates, alone or in combination with other drugs. Eligibility and approval are based on preliminary clinical evidence and indicate that the drug candidate may offer substantial improvement over existing therapies.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9179 USD | +2.10% | +13.87% | +13.32% |
Apr. 25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
Apr. 25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.32% | 90.83M | |
+29.68% | 681B | |
+20.41% | 556B | |
-4.35% | 361B | |
+17.65% | 325B | |
+3.77% | 285B | |
+14.49% | 235B | |
+4.38% | 199B | |
-10.96% | 189B | |
-3.79% | 157B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- HOOKIPA Pharma Inc. Announces European Medicines Agency Grant Prime Designation for the Investigational Product HB-200